Jeff Evanson - Jan 17, 2023 Form 4 Insider Report for Outlook Therapeutics, Inc. (OTLK)

Role: Chief Commercial Officer
Signature: /s/ Lawrence Kenyon, Attorney-in-Fact
Stock symbol: OTLK
Transactions as of: Jan 17, 2023
Transactions value $: -$203,726
Form type: 4
Date filed: 1/19/2023, 07:05 PM
Previous filing: Apr 4, 2022
Next filing: Jan 24, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	OTLK	Common Stock	Sale	-$35.6K	-27.2K	-2.31%	$1.31	1.15M	Jan 17, 2023	Direct	F1, F2
transaction	OTLK	Common Stock	Sale	-$42.2K	-33.7K	-2.93%	$1.25	1.12M	Jan 18, 2023	Direct	F1, F2
transaction	OTLK	Common Stock	Sale	-$126K	-103K	-9.25%	$1.22	1.01M	Jan 19, 2023	Direct	F1, F3

Showing 1 to 3 of 3 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares were sold to cover taxes upon lapse of Issuer's repurchase right as to 75% of the shares as provided in that certain Consulting Agreement dated January 27, 2020.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from within a $1.00 range. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F3	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.1909 - $1.265, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.